Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolbetuximab + CAPOX vs placebo + CAPOX in CLDN18.2-positive, HER2-negative gastric/GEJ cancer
CTR20190261Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of zolbetuximab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Astellas Pharma. Started Apr 2019; status: completed.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20190261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190261.